Here are 1-2 brief analogies for Entera Bio (ENTX):

• Entera Bio aims to be the Moderna of oral large molecule drug delivery, developing a platform technology to turn typically injectable therapies into convenient pills.
• Entera Bio is like Novo Nordisk for the broader category of large molecule drugs, aiming to convert many different injectable therapies into convenient oral pills.

• EB612: An investigational oral parathyroid hormone (PTH) analog currently being developed for the treatment of hypoparathyroidism.
• ENRA001: An investigational oral GLP-1 analog program aimed at treating obesity and type 2 diabetes.

As a clinical-stage biopharmaceutical company, Entera Bio (symbol: ENTX) is currently focused on the research and development of its product candidates, primarily an oral formulation of PTH (EB612) for the treatment of osteoporosis.

According to its most recent financial filings (e.g., 2023 10-K), Entera Bio has not generated any revenue from the sale of its product candidates to date. Therefore, the company does not currently have "major customers" in the traditional sense, as it is not selling commercial products to other companies or directly to individuals.

Entera Bio's primary activities involve conducting clinical trials and advancing its drug pipeline. Future revenue, if any, would likely come from product commercialization following regulatory approval, which could involve direct sales, licensing agreements, or partnerships with larger pharmaceutical companies.

Catalent Pharma Solutions, Inc. (CTLT)

Merck KGaA (MRK.DE)

Miranda Toledano, Chief Executive Officer

Miranda Toledano has served as Entera Bio's Chief Executive Officer since July 2022. She has over 25 years of C-level leadership, principal investment, and Wall Street/capital market experience in the biotech sector. Prior to joining Entera, Ms. Toledano was Chief Operating Officer, Chief Financial Officer, and a Board Member of TRIGR Therapeutics from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. Earlier in her career, she served as a vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano also serves as an Independent Director of Journey Medical Corporation since November 2021.

Dana Yaacov-Garbeli, Chief Financial Officer

Dana Yaacov-Garbeli has served as Entera Bio's Chief Financial Officer since June 2019, and as Chief Financial Officer and Principal Accounting Officer since July 2022. She brings over 17 years of finance and accounting experience, having previously served as a Senior Manager at PwC Israel where she oversaw audits of public and private companies and was involved in US IPO processes. Ms. Yaacov-Garbeli's experience includes CFO roles at Wilk (TLV: WILK) in 2017, Sonovia Ltd. in 2020, and Axilion Smart Mobility - AI (TLV:AILN) starting in 2022. She has also been a Partner at A2Z Finance - Israel since 2017, providing outsourced CFO and consulting services to various companies.

Hillel Galitzer, Chief Operating Officer

Dr. Hillel Galitzer has served as Entera Bio's Chief Operating Officer since February 2014, following his role as Director of Scientific Development from July 2010. Before joining Entera, Dr. Galitzer was an analyst and the Chief Operating Officer for Hadasit Bio Holdings Ltd. (TASE: HDST), a publicly traded company. He is also a co-founder and former Chief Operating Officer of Optivasive Inc.

Gregory Burshtein, Chief of Research and Development

Dr. Gregory Burshtein has led research and development at Entera Bio since September 2012, serving as Director of Pharmaceutical R&D and then as Chief of Research and Development since May 2024. He possesses over 20 years of experience in drug delivery, pharmacology, and biopharmaceutics, with a specialized focus on the oral delivery of therapeutic peptides. Dr. Burshtein holds 25 issued patents and 113 pending patent applications related to the development, formulation, and delivery of oral large molecules.

Arthur Santora, Chief Medical Officer

Dr. Arthur Santora was appointed as Entera Bio's Chief Medical Officer in September 2018. He has over 30 years of experience in the biopharmaceutical industry, with a significant portion of his career spent at Merck & Co., Inc. From June 1989 to March 2017, he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium) and was closely involved in the development of Fosamax Plus D. Dr. Santora began his career as a Medical Officer at the U.S. FDA.

A clear emerging threat to Entera Bio (ENTX) is the advanced development and recent regulatory approval of Ascendis Pharma's TransCon PTH (palopegteriparatide), marketed as Yorvipath in Europe. TransCon PTH is a long-acting parathyroid hormone (PTH) replacement therapy for hypoparathyroidism, which directly competes with Entera Bio's lead candidate, EB612, also for hypoparathyroidism. While EB612 aims to be an oral formulation, TransCon PTH (a once-daily injectable) has successfully completed Phase 3 trials, received European Union approval in November 2023, and is expected to receive U.S. regulatory approval in Q2 2024. This significantly earlier market entry and established efficacy profile of TransCon PTH pose a substantial and imminent competitive threat to EB612, potentially capturing a significant market share before Entera Bio's product can reach commercialization.

Entera Bio (ENTX) Addressable Markets:

• EB613 for Osteoporosis: The global osteoporosis drugs market was valued at approximately $16.6 billion in 2024 and is projected to reach around $25.4 billion by 2032. Another estimate for the global osteoporosis drugs market size is $16.88 billion in 2025, projected to reach $21.28 billion by 2030. The market for osteoporosis across the seven major markets (7MM) is forecasted to reach $17.9 billion in 2033. The U.S. osteoporosis treatment market size was valued at $4.80 billion in 2024 and is expected to reach $6.24 billion by 2032.

• EB612 for Hypoparathyroidism: The global hypoparathyroidism treatment market was valued at approximately $1.3 billion in 2023 and is projected to reach around $2.5 billion by 2031. Other estimations for the global market size include $1.25 billion in 2023, expected to reach $2.25 billion by 2032, and an estimated value of $787.4 million in 2025, reaching $1323.4 million by 2032. North America held a significant market share in the hypoparathyroidism market.

• Oral Oxyntomodulin (OXM) for Obesity/Metabolic Disorders: The addressable market for obesity is estimated to be a $100 billion global market.

• Oral GLP-2 for Short Bowel Syndrome (SBS): null

Entera Bio Ltd. (NASDAQ: ENTX) is a clinical-stage biopharmaceutical company focused on developing orally delivered macromolecule therapeutics, particularly peptides and therapeutic proteins. The company's future revenue growth over the next 2-3 years is primarily expected to be driven by the advancement and potential commercialization of its pipeline candidates, strategic collaborations, and the validation of its proprietary oral delivery platform.

Here are 3-5 expected drivers of future revenue growth:

1. Advancement and Potential Commercialization of EB613 for Osteoporosis: Entera Bio's lead product candidate, EB613, is an oral parathyroid hormone (PTH) analog designed for the treatment of post-menopausal women with high-risk osteoporosis. The company has completed a Phase 2 study and is anticipating a pivotal Phase 3 study. A significant driver is the FDA's potential landmark ruling, expected in January 2025, on the ASBMR-FNIH SABRE regulatory endpoint, which aims to qualify bone mineral density (BMD) as a surrogate endpoint for fractures. This ruling could streamline the regulatory pathway for EB613 by potentially allowing BMD as a primary endpoint for Phase 3 studies, which would be a major catalyst for the program. The company plans to initiate a Phase 1 study for a next-generation EB613 tablet candidate in the second half of 2025. The FDA has already provided pivotal agreement on using BMD as the primary endpoint for EB613's Phase 3 program, clearing a streamlined pathway for the first oral anabolic osteoporosis treatment.
2. Progress of EB612 for Hypoparathyroidism: EB612 is another oral PTH(1-34) peptide replacement therapy in Entera Bio's pipeline, aimed at treating hypoparathyroidism. The company has presented Phase 1 clinical data supporting the potential advancement of a twice-daily tablet dose to Phase 2 development in patients with hypoparathyroidism. Continued positive clinical development and eventual regulatory approval of EB612 would represent a significant new revenue stream.
3. Strategic Collaboration with OPKO Health for GLP-1/Glucagon and GLP-2 Programs: Entera Bio has a collaboration and license agreement with OPKO Health Inc. for the development of oral GLP-2 and GLP-1/Glucagon programs. This includes Oral OPK-88006, a first-in-class dual-acting GLP-1/Glucagon single tablet for metabolic diseases (such as obesity), which is expected to advance into SAD/MAD Phase 1 studies. Positive preclinical data for the oral GLP-1/glucagon dual agonist program has already been presented. The GLP-2 peptide tablets are being developed for short bowel syndrome and other gastrointestinal disorders. The funding from this collaboration also extends Entera Bio's cash runway, supporting ongoing operations and pipeline development.
4. Leveraging the N-Tab™ Oral Peptide Delivery Platform: Entera Bio's proprietary N-Tab™ platform is central to its strategy. This technology is designed to enable oral delivery of large peptide molecules, overcoming challenges of gastrointestinal absorption and offering convenient tablet alternatives to injectable formulations. The company's goal is to advance five potential first-in-class oral peptide programs into the clinic by the end of 2025, demonstrating the broad applicability and potential of its platform. Successful development and commercialization of new product candidates utilizing this platform, either independently or through partnerships, will be a key driver of long-term revenue growth.

Share Issuance

• In December 2023, Entera Bio closed a private placement, issuing 7,916,879 units (consisting of ordinary shares or pre-funded warrants, and five-year warrants) at a price of $0.835 per unit, generating approximately $6.6 million in gross proceeds. The exercise of all warrants could bring in an additional ~$7.9 million.
• During Q1 2025, Entera Bio significantly extended its cash runway into late 2026 through direct investment from "marquis investors" and its strategic partner, OPKO Health Inc.
• As of June 30, 2025, the number of outstanding ordinary shares increased to 45,452,167 from 38,837,220 as of December 31, 2024. This included an $8.0 million issuance of 3,685,226 shares to OPKO in 2025, placed in escrow to fund collaborative program costs.

Inbound Investments

• Entera Bio received a direct investment from marquis investors and its strategic partner, OPKO Health Inc., during Q1 2025, which is anticipated to extend the company's cash runway until mid-2026.
• In March 2025, Entera Bio established a collaboration and license agreement with OPKO Health for the Oral OXM program, where OPKO and Entera will hold 60% and 40% pro-rata ownership interests, respectively, and contribute to development costs.
• OPKO Health Inc. made a direct investment in Entera shares at $2.17 per share to cover the Phase 1 development costs for the Oral OPK-88006 program. This included an $8.0 million issuance to OPKO in 2025.

Capital Expenditures

• Capital expenditures for Q2 2025 were $29,000, marking a 262.50% increase from $8,000 in Q1 2025.
• For the fiscal year 2024, annual capital expenditures amounted to $3,000, an 82.35% decrease compared to the previous year.
• The 3-year average for capital expenditures is $9,500, with a median of $6,500 in 2023. These expenditures are primarily focused on supporting its clinical-stage biopharmaceutical operations, including advancing product candidates such as EB613 through regulatory activities and Phase 3 planning.